174 related articles for article (PubMed ID: 16716141)
1. Progressive esophagitis caused by Candida albicans with reduced susceptibility to caspofungin.
Miller CD; Lomaestro BW; Park S; Perlin DS
Pharmacotherapy; 2006 Jun; 26(6):877-80. PubMed ID: 16716141
[TBL] [Abstract][Full Text] [Related]
2. Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis.
Laverdière M; Lalonde RG; Baril JG; Sheppard DC; Park S; Perlin DS
J Antimicrob Chemother; 2006 Apr; 57(4):705-8. PubMed ID: 16464893
[TBL] [Abstract][Full Text] [Related]
3. Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis.
Hernandez S; López-Ribot JL; Najvar LK; McCarthy DI; Bocanegra R; Graybill JR
Antimicrob Agents Chemother; 2004 Apr; 48(4):1382-3. PubMed ID: 15047549
[TBL] [Abstract][Full Text] [Related]
4. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates.
Park S; Kelly R; Kahn JN; Robles J; Hsu MJ; Register E; Li W; Vyas V; Fan H; Abruzzo G; Flattery A; Gill C; Chrebet G; Parent SA; Kurtz M; Teppler H; Douglas CM; Perlin DS
Antimicrob Agents Chemother; 2005 Aug; 49(8):3264-73. PubMed ID: 16048935
[TBL] [Abstract][Full Text] [Related]
5. Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1.
Balashov SV; Park S; Perlin DS
Antimicrob Agents Chemother; 2006 Jun; 50(6):2058-63. PubMed ID: 16723566
[TBL] [Abstract][Full Text] [Related]
6. Acquired resistance to echinocandins in Candida albicans: case report and review.
Baixench MT; Aoun N; Desnos-Ollivier M; Garcia-Hermoso D; Bretagne S; Ramires S; Piketty C; Dannaoui E
J Antimicrob Chemother; 2007 Jun; 59(6):1076-83. PubMed ID: 17468115
[TBL] [Abstract][Full Text] [Related]
7. Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy.
Hakki M; Staab JF; Marr KA
Antimicrob Agents Chemother; 2006 Jul; 50(7):2522-4. PubMed ID: 16801435
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of Candida albicans CDR1, CDR2, or MDR1 does not produce significant changes in echinocandin susceptibility.
Niimi K; Maki K; Ikeda F; Holmes AR; Lamping E; Niimi M; Monk BC; Cannon RD
Antimicrob Agents Chemother; 2006 Apr; 50(4):1148-55. PubMed ID: 16569823
[TBL] [Abstract][Full Text] [Related]
9. The echinocandins.
Cappelletty D; Eiselstein-McKitrick K
Pharmacotherapy; 2007 Mar; 27(3):369-88. PubMed ID: 17316149
[TBL] [Abstract][Full Text] [Related]
10. Anti-metabolic activity of caspofungin against Candida albicans and Candida parapsilosis biofilms.
Cocuaud C; Rodier MH; Daniault G; Imbert C
J Antimicrob Chemother; 2005 Sep; 56(3):507-12. PubMed ID: 16040622
[TBL] [Abstract][Full Text] [Related]
11. Response and relapse rates of candidal esophagitis in HIV-infected patients treated with caspofungin.
Dinubile MJ; Lupinacci RJ; Berman RS; Sable CA
AIDS Res Hum Retroviruses; 2002 Sep; 18(13):903-8. PubMed ID: 12230933
[TBL] [Abstract][Full Text] [Related]
12. Elevated cell wall chitin in Candida albicans confers echinocandin resistance in vivo.
Lee KK; Maccallum DM; Jacobsen MD; Walker LA; Odds FC; Gow NA; Munro CA
Antimicrob Agents Chemother; 2012 Jan; 56(1):208-17. PubMed ID: 21986821
[TBL] [Abstract][Full Text] [Related]
13. Caspofungin versus amphotericin B for the treatment of Candidal esophagitis.
Chocarro Martínez A; Gonzalez A; Garcia I
Clin Infect Dis; 2002 Jul; 35(1):107; author reply 107-8. PubMed ID: 12060888
[No Abstract] [Full Text] [Related]
14. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
15. [Successful treatment with caspofungin of an invasive candidosis resistant to liposomal amphotericin B in a neutropenic patient].
Rome A; André N; Michel A; Coze C; Gentet JC; Bernard JL
Arch Pediatr; 2006 Dec; 13(12):1556-7. PubMed ID: 17049216
[No Abstract] [Full Text] [Related]
16. Serum differentially alters the antifungal properties of echinocandin drugs.
Paderu P; Garcia-Effron G; Balashov S; Delmas G; Park S; Perlin DS
Antimicrob Agents Chemother; 2007 Jun; 51(6):2253-6. PubMed ID: 17420211
[TBL] [Abstract][Full Text] [Related]
17. Sequential therapy with caspofungin and fluconazole for Candida albicans infection.
Barchiesi F; Spreghini E; Baldassarri I; Marigliano A; Arzeni D; Giannini D; Scalise G
Antimicrob Agents Chemother; 2004 Oct; 48(10):4056-8. PubMed ID: 15388480
[TBL] [Abstract][Full Text] [Related]
18. Topical caspofungin for treatment of keratitis caused by Candida albicans in a rabbit model.
Goldblum D; Frueh BE; Sarra GM; Katsoulis K; Zimmerli S
Antimicrob Agents Chemother; 2005 Apr; 49(4):1359-63. PubMed ID: 15793112
[TBL] [Abstract][Full Text] [Related]
19. Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro.
Jacobsen MD; Whyte JA; Odds FC
Antimicrob Agents Chemother; 2007 May; 51(5):1882-4. PubMed ID: 17307974
[TBL] [Abstract][Full Text] [Related]
20. Tolerance to Caspofungin in Candida albicans Is Associated with at Least Three Distinctive Mechanisms That Govern Expression of
Yang F; Zhang L; Wakabayashi H; Myers J; Jiang Y; Cao Y; Jimenez-Ortigosa C; Perlin DS; Rustchenko E
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28223384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
